An open-label, first in human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk myelodysplasia (HR-MDS).

  • Fleming, Shaun Alan (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Effective start/end date11/11/2131/12/26


  • Malignant Haematology
  • Clinical trial